TZDs are PPARγ agonists used as antidiabetic drugs, whose mechanism of action induces a decrease in plasma free fatty acid concentrations and fasting hyperglycemia via an insulin-sensitizing effect [14]. The gene discussed is INS; the disease is Hyperglycemia.